💉 One Shot, Lifelong LDL reduction? The Promise of Genomic Cardiology

🧬 Could a single infusion replace decades of lipid-lowering therapy?   The new NEJM study on VERVE-102 explores in vivo base editing of PCSK9 using CRISPR-inspired adenine base editing technology. In this phase 1 trial, a one-time infusion produced LDL cholesterol reductions up to 62% with durable effects extending beyond 1 year. ❤️   This may represent a major shift from chronic pharmacotherapy toward "once-and-done" genomic cardiovascular prevention.   The science, safety, clinical implications, and future of gene-editing cardiology on "Dr RR Baliga's Podkast for the Kurious Doc." 🎙️🧠   #Cardiology #CRISPR #PCSK9 #PrecisionMedicine #Genomics #LDL #NEJM #MedicalInnovation #PreventiveCardiology #medicalpodca